Who
Sanjay Subramanian
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Scynexis; SVP, CFO & Head of BD, Inozyme Pharma; Chief Financial Officer, Ocugen.
In numbers
- Trades disclosed
- 48
- Buys
- 3
- Sells
- 7
- Bought
- $111K
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Oct 2019
- Last trade
- 9 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 11 Sep 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 9 Sep 2026filed 11 Sep 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —38,500 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —180,000 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —135,000 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —145,000 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharma | SEC FORM 4 Code U | $159K39,701 at $4.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Inozyme Pharma | SEC FORM 4 Code A | $5,0426,813 at $0.74 | filing |
| 31 Mar 2025filed 2 Apr 2025 | Inozyme Pharma | SEC FORM 4 Code A | $1,9172,490 at $0.77 | filing |
| 11 Mar 2025filed 17 Mar 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 11 Mar 2025filed 17 Mar 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —38,500 at $0.00 | filing |
| 13 Mar 2024filed 15 Mar 2024 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —165,000 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | Inozyme Pharma | SEC FORM 4 Code A | $8,2792,319 at $3.57 | filing |
| 31 Mar 2023filed 4 Apr 2023 | Inozyme Pharma | SEC FORM 4 Code A | $2,164979 at $2.21 | filing |
| 23 Mar 2023filed 27 Mar 2023 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 19 Apr 2022filed 20 Apr 2022 | Inozyme Pharma | SEC FORM 4 Bought | $100K27,100 at $3.69 | filing |
| 21 Mar 2022filed 22 Mar 2022 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —454,007 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | OCGN OcugenBiotechnology | SEC FORM 4 Code A | —125,534 at $0.00 | filing |
| 16 Dec 2021filed 17 Dec 2021 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,560 at $0.00 | filing |
News
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaOCGN · manilatimes.net · 14 Oct 2026Ocugen (NASDAQ:OCGN) Stock: Insider Shankar Musunuri Sells 468,727 SharesOCGN · tickerreport.com · 14 Oct 2026Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?OCGN · prnewswire.com · 8 Oct 2026
0 headlines in the last 90 days name Sanjay Subramanian; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.